Abstract Emerging evidence points to an unexpected diversification of core promoter recognition complexes that serve as important regulators of cell-type specific gene transcription. Here, we report that the orphan TBP-associated factor TAF9B is selectively up-regulated upon in vitro motor neuron differentiation, and is required for the transcriptional induction of specific neuronal genes, while dispensable for global gene expression in murine ES cells. TAF9B binds to both promoters and distal enhancers of neuronal genes, partially co-localizing at binding sites of OLIG2, a key activator of motor neuron differentiation. Surprisingly, in this neuronal context TAF9B becomes preferentially associated with PCAF rather than the canonical TFIID complex. Analysis of dissected spinal column from Taf9b KO mice confirmed that TAF9B also regulates neuronal gene transcription in vivo. Our findings suggest that alternative core promoter complexes may provide a key mechanism to lock in and maintain specific transcriptional programs in terminally differentiated cell types.
Introduction
Sequence-specific transcription factors are essential for directing cellular differentiation and identity. These factors play key roles in establishing gene expression patterns that dictate cell-type specific functions and characteristics. Cellular reprogramming and de-differentiation leading to the formation of induced pluripotent stem cells offer dramatic examples of how targeted expression of particular sets of transcription factors can control cell fate (reviewed by Graf, 2011) . Sequence-specific transcription factors work in concert with a cohort of co-activator complexes and core promoter recognition factors to execute transcriptional activation. These core promoter factors often called 'basal' or 'general' transcription factors have traditionally been considered invariant and universally required for the expression of all protein-coding genes. However, recent studies suggest that at least some components of this large and diverse group of factors necessary to form the transcriptional pre-initiation complex (PIC) can exhibit both promoter and enhancer targeting activities that are cell-type specific. This specificity depends on the variegated composition of the components in the PIC (reviewed in D' Alessio et al., 2009; Goodrich and Tjian, 2010; Müller et al., 2010) .
The first evidence of tissue-specific functions of core PIC factors came from studies of TAF (TBPassociated factors) subunits in the core promoter recognition factor TFIID. A paralog of TAF4, called TAF4B, was found to control oocyte-specific activation of transcription in mouse ovaries (Freiman et al., 2001) . In Drosophila, a group of five TAF paralogs (No hitter/TAF4; Cannonball/TAF5; Meiois I arrest/TAF6; Spermatocyte arrest/TAF8; and Ryan express/TAF12) all play specific roles in spermatogenesis (Hiller et al., 2004; Chen et al., 2005) . Similarly, another orphan TAF, TAF7L, cooperates with TBP-related factor 2 (TRF2) to regulate spermatogenesis in mice (Cheng et al., 2007; eLife digest Almost all the cells in an organism contain the same genetic information, but they develop into many different types of cells that perform a variety of specialized functions in the body. Brain cells, for example, have a very different shape and function from red blood cells. A small group of proteins act inside cells to switch on the expression of genes it needs to carry out the specific functions of a given cell-type, and switch off the genes that are only needed in other cell types.
Some of these regulatory proteins called 'core promoter factors' bind to the DNA near the start of genes. These core factors are known to work in combination with various other proteins to switch genes on or off in specific cell types. However, the specific core promoter factors and partner proteins that guide a cell into becoming a neuron have not been well characterized. Now, Herrera et al. have identified a core promoter factor called TAF9B that is produced at higher levels when mouse stem cells are coaxed into becoming the motor neurons that carry nerve impulses to muscles. The TAF9B protein works together with an enzyme (called PCAF) to help to switch on the genes that control the development of these cells. Without this regulatory protein, mouse stem cells grown in the lab fail to properly switch on the genes that are necessary to become motor neurons. These mutant stem cells also fail to efficiently switch off genes that stop stem cells from becoming more specialized. High levels of TAF9B were also found in the spinal cord of newborn mice and when Herrera et al. engineered mice that lack TAF9B, these mice did not properly regulate the expression of neuronal genes in their spines.
These new findings might, in the future, improve our ability to guide stem cells into forming neurons, or to reprogram other types of specialized cells into becoming motor neurons. This new information could also prove useful for researchers interested in better understanding neuronal development and might aid in the design of therapies to treat neuronal injuries or diseases, such as motor neuron disease. 
Results

TAF9B is up-regulated upon neuronal differentiation
To examine whether the expression of various components of the core promoter recognition complex changes upon neuronal differentiation, we induced ES cells to form motor neurons using retinoic acid (RA) and the smoothened agonist SAG as described previously (Wichterle et al., 2002) . We confirmed the generation of motor neurons in embryoid bodies (EBs) by immunostaining for motor neuronspecific markers LHX3 and ISL1/2 ( Figure 1A) as well as by RNA-seq analysis (Figure 1-figure  supplement 1A) . To obtain enriched populations of motor neurons, we differentiated a murine ES cell line containing a motor neuron-specific promoter (Mnx1) fused to GFP as a means of isolating postmitotic motor neurons present in these EBs ( Figure 1B, Figure 1-figure supplement 1B ; Wichterle et al., 2002) . Using this highly enriched motor neuron cell population, we compared the mRNA expression levels of genes coding for canonical TAF subunits in TFIID as well as various TAF paralogs ( Figure 1C ). As seen in other differentiated cell types, several TAFs are down-regulated upon motor neuron differentiation (Figure 1 ; Deato and Tjian, 2007; D'Alessio et al., 2011; Zhou et al., 2013b; Guermah et al., 2003) . Intriguingly, one TAF paralog (Taf9b) was significantly up-regulated in GFP expressing (GFP+) motor neurons but not in the GFP negative (GFP−) cells ( Figure 1C) . We confirmed that the up-regulation of TAF9B and down-regulation of several other TAFs occur at the level of both mRNA and protein ( Figure 1D) , and follows the kinetics of post-mitotic neuronal marker Tubb3 but not the progenitor cell markers Pax6 and Olig2 (Figure 1-figure supplement 1C) . We next dissected spinal cord tissue from newborn mice and performed RNA-seq to measure in vivo Taf expression levels and compare them to those observed for mouse ES cells in culture. As expected, most Taf subunits of TFIID in newborn spinal cord are expressed at lower levels than in mouse ES cells, while Taf9b is up-regulated more than 10-fold, consistent with the results obtained with the in vitro differentiated motor neurons ( Figure 1E) . Notably, changes in the expression levels of Tafs in newborn spinal cord are more pronounced than what we observed for the in vitro differentiated motor neurons. We also found that many components of the PIC and selected co-activators were down-regulated upon neuronal differentiation (Figure 1-figure supplement 1D and 1E) . These results strongly suggest that induction of TAF9B upon neuronal differentiation is specific and distinct from regulated expression of most other subunits of the PIC.
TAF9B is dispensable for global gene expression in mouse ES cells
To test the function of TAF9B in mouse ES cells and during motor neuron differentiation, we used Taf9b knock-out (KO) ES cells generated by the trans-NIH Knock-Out Mouse Project (KOMP). In these cells, all protein-coding exons of Taf9b have been replaced with the LacZ-Neo cassette ( Figure 2A) . As expected, the induction of Taf9b upon motor neuron differentiation was detected only in wild type (WT) cells but not in Taf9b KO cells (Figure 2B, C) . We found that Taf9b KO cells have a normal mouse ES cell morphology and can be grown in the presence of LIF without displaying any obvious cell growth or cell cycle defects ( Figure 2D and data not shown). To determine the role of TAF9B in regulating transcription in murine ES cells, we performed RNA-seq analysis to compare global gene expression patterns in WT and Taf9b KO cells. The results show that TAF9B is largely dispensable for global gene expression with only a small number of genes deregulated under these conditions ( Figure 2E ). Interestingly, whereas the core TAF components of TFIID have recently been reported to be critical for murine ES cell pluripotency and in controlling genes such as Pou5f1, Nanog and Klf4 (Pijnappel et al., 2013) , the absence of TAF9B did not affect expression of pluripotency markers ( Figure 2E,F) . These results suggest that, unlike other TAFs present in the canonical TFIID complex, TAF9B is dispensable for global gene expression and pluripotency of murine ES cells.
TAF9B is required for efficient differentiation of motor neurons
We next tested whether TAF9B is required for efficient in vitro motor neuron differentiation. ES cells were differentiated as described previously and motor neuron markers Isl1, Mnx1, and Lhx3 were measured by qRT-PCR. We observed a significant reduction in all motor neuron markers in Taf9b KO cells upon differentiation ( Figure 3A) . Immunostaining for motor neuron marker ISL1/2 as well as western blot analysis for TUBB3 further confirmed that motor neuron differentiation was compromised in Taf9b KO cells ( Figure 3B,C) . We next measured the down-regulation of ES specific markers Pou5f1 and Nanog upon differentiation and found that Taf9b KO cells failed to efficiently down-regulate these ES cell markers ( Figure 3A) . Immunostaining of OCT4 and NANOG confirmed that a fraction of cells in these neuralized EBs derived from Taf9b KO cells continue to express pluripotency markers, whereas few or no cells expressing OCT4 and NANOG were detected in WT cells ( Figure 3B ). Consistent with the maintenance of an undifferentiated state, a higher number of dividing cells persisted in Taf9b KO EBs as determined by the marker for cellular proliferation Ki67 ( Figure 3B ). We also found an increase in apoptosis in Taf9b KO cells compared to WT controls during early stages of differentiation ( Figure 3D ). These differences in apoptosis were particularly prominent at day 4 when progenitor cells are most enriched. This is consistent with previous observations implicating TAF9B in cell survival and control of apoptosis in human HeLa cells (Chen and Manley, 2003; Frontini et al., 2005) . Taken in aggregate, our findings suggest that TAF9B is required for the efficient in vitro differentiation of murine ES cells into motor neurons, and that the absence of TAF9B causes the persistent expression of pluripotency markers under differentiation conditions.
Efficient induction of neuronal genes requires TAF9B
To obtain a more comprehensive view of the role of TAF9B during motor neuron differentiation, we performed RNA-seq analysis at regular intervals during in vitro motor neuron differentiation of WT and Taf9b KO ES cells. We found that as motor neuron differentiation progressed there was a concomitant increase in the number of genes deregulated by the loss of TAF9B ( Figure 4A ). Striking deregulation of genes in Taf9b KO cells was observed at the time point at which progenitor cells are most enriched in these cultures (day 4). Genes known to be important for neuronal progenitor identity such as Olig2, Pax6, Sox1, Gli1 , and genes controlled by the Notch signaling pathway were among the most down-regulated by the loss of TAF9B ( , which is consistent with the increase in apoptosis levels we observed in Taf9b KO cells at this time point. By day 6, when post-mitotic motor neurons are normally present in these cultures, approximately 10% of all expressed genes were down-regulated and another 10% were up-regulated in Taf9b KO cells. This finding suggests that TAF9B is specifically required for the appropriate expression of a subset of genes, rather than for global gene expression in these differentiated EBs. The most significant GO term categories of genes down-regulated by the loss of TAF9B in this time point included genes involved in neuron differentiation, axogenesis, and neuron projection ( Figure 4C ). Moreover, the specific motor neuron markers Lhx3, Lhx4, Isl1, Mnx1, and pan-neuronal marker Tubb3 were among the most down-regulated genes in Taf9b KO cells ( Figure 4B ). In contrast, genes up-regulated in Taf9b KO cells were enriched in categories such as vascular development, stem cell maintenance, and other non-neuronal developmental categories ( Figure 4C ). Contrary to the large number of genes deregulated in neuralized EB samples, we found that samples differentiated for 2 days have a relatively small number of genes affected in Taf9b KO cells. Interestingly, genes involved in differentiation were still found among these early down-regulated genes (Supplementary file 1) . These results indicate that TAF9B controls the expression of specific genes required at least for the in vitro differentiation of murine ES cells into motor neurons.
TAF9B binds promoters and distal regions of neuronal genes
To determine whether TAF9B acts directly to regulate neuronal genes we mapped its binding sites genome-wide by ChIP-seq. Because most TAFs are expected to bind to promoters as part of TFIID in the PIC, we compared ChIP-seq peaks of TAF9B with those of RNA POL2. Approximately a third of all detected TAF9B binding regions overlapped with RNA POL2 occupancy (TAF9B-POL2) and mapped generally near transcription start sites (TSS) of protein coding genes ( Figure 5A , Figure 5 -figure supplement 1B,C). However, TAF9B peaks located at TSS were not enriched at promoters of neuronal specific genes ( Figure 5B) . Intriguingly, approximately two thirds of all TAF9B binding regions showed little or no overlap with regions of high RNA POL2 occupancy (TAF9B-only) and were generally located distal to annotated TSS ( Figure 5A, Figure 5-figure supplement 1B, 1C) . Importantly, genes with TAF9B bound to regions distal to their TSS were significantly enriched in neuronal genes categories, including GO terms such as midbrain-hindbrain boundary development, rostrocaudal neural tube patterning and dorsal spinal cord development ( Figure 5B) . Several of the most down-regulated genes in the absence of TAF9B detected by RNA-seq (e.g., Neurog2 and Lhx4) were associated with TAF9B distal binding sites ( Figure 5-figure supplement 1A,E) . Moreover, genes bearing distal TAF9B peaks (e.g., 500-5000 bp from TSS) showed a higher percentage of genes down-regulated in Taf9b KO neuralized EBs than control gene sets ( Figure 5-figure supplement 1D) . Collectively, these results suggest that distal TAF9B binding sites are likely functional regulatory elements controlling neuronal genes. We subsequently compared the binding sites of TAF9B to the binding sites of OLIG2, a key transcriptional activator involved in motor neuron differentiation mapped previously (Mazzoni et al., 2011) . We found co-localization between TAF9B and OLIG2 at both the TAF9B distal peaks and at the TAF9B TSS peaks, suggesting that TAF9B and OLIG2 act in concert at a subset of neuronal genes to regulate gene expression during motor neuron development ( Figure 5C ). The incomplete overlap of TAF9B and OLIG2 peaks may in part represent intrinsic differences between progenitor cells and postmitotic neurons, since the OLIG2 binding was performed with neuralized EBs enriched for progenitor cells while TAF9B mapping was done with EBs enriched for post-mitotic motor neurons. In addition, it is likely that TAF9B co-localizes with activators other than OLIG2 in this developmental pathway.
TAF9B is associated with a PCAF-containing complex
Some TAFs are known to be part of not only the TFIID complex but also the SAGA complex (Spt-AdaGcn5-acetyltransferase), which can mediate histone acetylation and deubiquitination (reviewed by Spedale et al., 2012) . In human HeLa cells, TAF9B had previously been reported to be a component of both the TFIID and SAGA complexes (Frontini et al., 2005) . To test whether TAF9B in mouse neurons is primarily associated with TFIID or SAGA-like complexes, we performed co-immunoprecipitation (co-IP) experiments with antibodies against TAF9B using in vitro differentiated motor neurons. We observed little detectable association of TAF9B with TAF4 and TAF7, core components of the TFIID complex, while TBP antibodies co-IP'ed those TFIID components efficiently. In contrast, we observed an association between TAF9B and PCAF, a histone acetyltransferase present in the mammalian SAGA complex ( Figure 6A) . Immunoprecipitations of 293T cells transfected with flag-tagged versions of TAF9B or TAF9 confirmed that these IPs are specific for TAF9B and not the closely related TAF9 subunit ( Figure 6B) . We also performed TAF9B co-IP experiments on dissected spinal column tissue samples from WT and Taf9b KO newborn mice, confirming that the interactions between TAF9B and PCAF occur in vivo ( Figure 6C) . Thus, TAF9B primarily associates with PCAF likely in a SAGA-like complex rather than the canonical TFIID in murine neurons.
TAF9B controls neuronal gene expression in vivo
To test the in vivo role of TAF9B during neuronal development, we generated a KO mouse using the Taf9b KO ES cells obtained from KOMP (Figure 7-figure supplement 1A) . Taf9b KO mice were viable and fertile, though the number of pups and birth weights were reduced in Taf9b KO matings compared to WT controls (Figure 7-figure supplement 1C) . As expected, spinal cord isolated from newborn KO animals did not express TAF9B ( Figure 7A,B, Figure 7-figure supplement 1D) . Given that Taf9b KO cells in vitro showed clear de-regulation of genes in both progenitor cells and postmitotic motor neurons (Figure 4) , we surmised that loss of TAF9B in vivo may affect not only motor neuron formation but perhaps also proper differentiation of other cell types present in the spinal cord. To test whether neuronal gene expression in vivo is specifically affected in the absence of TAF9B, we carried out RNA-seq analysis to compare whole lumbar spinal column tissue dissected from newborn WT and KO littermates ( Figure 7C ). Our data indicate that genes down-regulated in the absence of TAF9B are enriched for neuronal genes including gene categories such as neuron projection, synapse and axonogenesis ( Figure 7D ). Among the down-regulated genes identified by RNA-seq were neuronal genes such as Map1b, L1cam, Nefm, Nefh, and Isl2. Gene expression analysis by qRT-PCR of lumbar spinal column tissues confirmed that those neuronal genes are consistently downregulated in KO compared to WT littermate controls ( Figure 7E ). Several different markers of specific neuronal populations, as well as the general marker Tubb3, were also affected in the absence of TAF9B, suggesting a global defect in neuronal gene expression in the spinal cord ( Figure 7 figure supplement 1E; Supplementary file 2). These results are also consistent with a global reduction in neuronal tissue compared to surrounding non-neuronal tissue in the dissected spinal column preparations. Our data suggest that the observed pan-neuronal down-regulation and loss of neuronal tissue may be due to problems in the control of gene expression that coordinates the precise differentiation of progenitor cells during neuronal development. These in vivo results taken together with our in vitro differentiation studies strongly support the notion that TAF9B is specifically required for the regulation of neuronal genes during neuronal development in the spinal cord.
Discussion
The control of tissue-specific gene expression has been largely attributed to the combinatorial action of transcriptional activators and repressors. These regulatory factors are thought to interact in concert with a highly conserved and prototypic set of core promoter recognition proteins and co-activators that form the PIC at gene promoters. However, this model has been challenged by different studies demonstrating changes that occur in the core promoter machinery in a tissue-specific manner (reviewed by D' Alessio et al., 2009; Goodrich and Tjian, 2010) . Despite the emerging roles that these core promoter components play in regulating cell-type specific gene expression, relatively little was known about possible changes that may occur in the composition of core promoter factors during neuronal differentiation. In this study, we screened for changes in the expression of core promoter factors including TAFs, general transcript factors (GTFs), and mediator subunits (MEDs) upon neuronal differentiation. We found that most of the components in the mammalian PIC are expressed at relatively low levels in dissected spinal cord tissue compared to ES cells. Likewise, we observed down-regulation of several of these core promoter recognition components during in vitro differentiation of murine ES cells into motor neurons. By contrast, one orphan TAF, TAF9B, becomes highly up-regulated during motor neuron formation. Using a loss-of-function approach, we found that TAF9B is required for the efficient expression of neuronal genes upon in vitro motor neuron differentiation. Importantly, we found that TAF9B is dispensable for global gene expression in undifferentiated ES cells in contrast to the critical role that other TAFs in TFIID play in these cells (Pijnappel et al., 2013) . Using ChIP-seq, we found that TAF9B binds promoter and distal regulatory regions of neuronal genes co-localizing in a subset of regions with OLIG2, a key regulator of motor neuron differentiation. Strikingly, Taf9b KO mice showed defects in the expression of neuronal genes examined by transcriptome analysis of whole spinal column tissues. Importantly, the mechanism by which TAF9B mediates neuronal-specific transcription programs is unlike all previous TAF involvement in cell specific function: rather than operating through TFIID or distal enhancer complexes (Freiman et al., 2001; Liu et al., 2011; Zhou et al., 2013b) , it associates with a SAGA/PCAF co-activator complex.
Our results and those of several other studies probing tissue-specific activities of core promoter factors and co-activators suggest a model in which changes in these complexes are integral to the transcriptional program leading to terminal differentiation. Different cell types employ distinct combinations of activators that must engage in specific protein-protein interactions with core promoter factors. We speculate that rather than existing as a static complex awaiting recruitment by these transcription factors, core promoter complexes themselves must undergo compositional changes using cell type-specific components such as TAF9B. These alternative promoter complexes expand the diversity and number of possible protein-protein transactions necessary to achieve proper fine-tuned control of gene expression. Furthermore, we speculate that such diversified core machineries might provide a mechanism to help lock down and maintain the functions and identity of differentiated cell types. We imagine that in a given cell type, if the silencing of an undesirable activator or repressor is imperfect, their specific interacting partners in the targeted core machinery may nevertheless not be present, thus serving as a fail safe mechanism to prevent unscheduled alterations in programs of gene transcription. We suspect that such core promoter complex dependent control and maintenance of cell identity would likely be accompanied by activator selectivity and integrated with changes in chromatin structure and other layers of regulation that must work coordinately to keep expression patterns stable yet responsive to different stimuli in terminally differentiated cells. We anticipate that further analysis of adult neuronal cell-types as well as other differentiated somatic cells will bring new insights regarding the use of alternative core machineries that regulate gene expression in normal and disease states.
To start addressing these questions in the context of tissues in vivo, we generated Taf9b KO mice. We found that mice lacking TAF9B are viable, indicating that this orphan TAF is either not critical for normal development of cell-types other than neurons or its function is partly redundant with the closely related TAF9 homolog. We established that indeed Taf9 is highly expressed in both mouse ES cells and neurons (as detected by RNA-seq). It is possible that TAF9 partially compensates for the loss of TAF9B thus blunting further global gene expression defects in Taf9b KO cells. In human HeLa and chicken DT40 cells partially redundant functions have been observed for these paralogs (Chen and Manley, 2003; Frontini et al., 2005) . It will be interesting to test whether Taf9 KO mouse are viable and whether the double KO of these two related genes (Taf9 and Taf9b) results in more pronounced phenotypes. No Taf9 KO mice have been reported to date. Taf4b and Taf7l KO mice are also viable, but unlike Taf9b KO mice, they are infertile (Freiman et al., 2001; Falender, 2005; Zhou et al., 2013a) . Our results suggest that TAF9B is not critical for gametogenesis, in contrast to what has been observed for these two other orphan TAFs. Instead, our results point to a model where TAF9B is involved in the activation of neuronal genes by binding to distal and promoter proximal DNA regulatory elements associated with the histone acetyltransferase PCAF that, like its paralog GCN5, are subunits of the SAGA/STAGA/TFTC complex. This complex contains several TAFs shared with TFIID including TAF6, TAF9, TAF5, TAF10, TAF12, and a de-ubiquitinase (DUB) module that removes ubiquitin from histone H2B (reviewed by Spedale et al., 2012; Weake and Workman, 2012) . Because TAFs are structural components of both SAGA and TFIID complexes, it is possible that TAF9B is affecting the competitive recruitment or activity of a SAGA-like complex in place of TFIID.
Among the genes affected by the loss of TAF9B are several targets of the Notch-and Shh-signaling pathway, both known to play key roles in neuronal development (reviewed by Louvi and ArtavanisTsakonas, 2006; Jessell, 2000) . Interestingly, several lines of evidence connect the activation of Notch dependent genes with the PCAF-containing complex providing a potential link between PCAF, TAF9B, and activation of these genes. For example, PCAF has been shown to cooperate with another coactivator protein, p300, in Notch intracellular domain-dependent transcription assays using chromatin templates in vitro, as well as in transfection/reporter assays (Kurooka and Honjo, 2000; Wallberg et al., 2002) . Other components of the SAGA complex have been linked to the specific control of gene expression in cells of the central nervous system. Mutations in two subunits of the Drosophila DUB complex, Nonstop and Sgf11, lead to defects in neural development in the optic lobe (Weake et al., 2008) . In mice, mutations in the HAT domain of GCN5 result in defects in cranial neural tube closure and embryonic lethality (Bu et al., 2007) . In humans, mutations in the DUB subunit ATXN7 are associated with the development of spinocerebellar ataxia type 7, a disease characterized by the loss of motor control as well as retinal defects (reviewed by Koutelou et al., 2010) . Interestingly, we observed that Taf9b KO mice display defects in eye development including microphthalmia and cataractslike phenotypes albeit with modest penetrance (data not shown). The type of neuronal-specific role performed by TAF9B is reminiscent of the cell-type specific roles of particular subunits of the ATPdependent chromatin remodeling complex BAF. This complex undergoes changes in composition upon neuronal differentiation as specific BAF subunits are incorporated in neuronal progenitors cells as well as in post-mitotic neurons (Olave et al., 2002; Lessard et al., 2007) .
In this study, we have focused on characterizing the molecular phenotypes and have documented defects in gene regulation due to the absence of TAF9B during in vitro differentiation of motor neurons and in vivo in spinal column tissues. It is also possible that the down-regulation of neuronal genes observed in whole spinal column tissues in Taf9b KO mice may represent a specific loss of neuronal tissue relative to the surrounding vertebrae due perhaps to defects in neuronal progenitor cells during embryonic development. In future experiments, we hope to address the extent of potential neurological defects in Taf9b KO mice, including deficits in motor skills as well as other potential neurological defects due to the role that TAF9B may be playing in other neuronal populations besides motor neurons. Preliminary experiments using Taf9b KO mice carrying the LacZ reporter gene suggest that Taf9b is highly expressed in the developing hypothalamus at mid-gestation (data now shown). In a recent study describing neuronal activity-dependent ribosome profiling in the adult mouse hypothalamus (Knight et al., 2012) , Taf9b can be identified in the genomic data set as highly expressed in this tissue compared to several other TAFs. Moreover, the levels of Taf9b mRNA associated with ribosomes increased when neurons in the hypothalamus were activated, while several other TAFs were expressed at low levels or not enriched in a neuronal activity-dependent manner. These results suggest that TAF9B may be involved in setting up transcriptional responses in at least certain neuronal circuits in the hypothalamus. In the future, it will be interesting to directly test the role of TAF9B in the adult hypothalamus and to extend the analysis to other adult neuronal types.
Materials and methods
Cell culture
Murine embryonic stem cells were grown in embryoMAX DMEM (EMD Millipore, Billerica, MA) supplemented with LIF and 15% FBS. Cells were differentiated into embryoid bodies enriched in motor neurons (EB-MN) as described previously (Wichterle et al., 2002) . 2 × 10 5 cells/ml were incubated in differentiation media (25% embryoMAX DMEM, 25% F12 media, 25% neurobasal media, 1x B27 supplement, 1.5 mM L-glutamine and 0.1 mM β-mercaptoethanol) supplemented with 1 μM retinoic acid and 0.8 μM smoothened agonist SAG (N-Methyl-N′-[3-pyridinylbenzyl]-N′-[3-chlorobenzo{b}thiophene-2-carbonyl]-1,4-diaminocyclohexane, VWR, Radnor, PA) for up to 8 days. Samples were collected at different times as indicated. SHH conditioned media was generated by transfecting 293T cells with a vector expressing Shh-N and used when noted. The Notch signaling pathway inhibitor DAPT (N-[N-{3,5-difluorophen-acetyl}-l-alanyl]-S-phenylglycine t-butyl ester, Tocris Bioscience, United Kingdom) was added when noted to deplete progenitor cells and enrich for post-mitotic neurons in the culture (Crawford and Roelink, 2007) . The Taf9b KO mouse ES cells (Taf9b tm1(KOMP)Vlcg ) were generated by the trans-NIH Knock-Out Mouse Project (KOMP) and obtained from the KOMP Repository (www.komp.org). NIH grants to Velocigene at Regeneron Inc (U01HG004085) and the CSD Consortium (U01HG004080) funded the generation of gene-targeted ES cells for 8500 genes in the KOMP Program and archived and distributed by the KOMP Repository at UC Davis and CHORI (U42RR024244). We confirmed the described deletion by DNA sequencing (data not shown). Since the Taf9b gene is located in the X chromosome this male KO ES cells are a complete null for this gene. JM8 WT murine ES cells are from the same genetic background as Taf9b KO ES cells (C57BL/6). JM8 and Taf9b KO ES cells were grown on MEF feeder layers inactivated with mitomycin C (Sigma-Aldrich, St. Louis, MO). Murine ES cells carrying a GFP reporter under Mnx1 promoter (HBG3) were described previously (Wichterle et al., 2002) .
qRT-PCR
Total RNA was isolated using RNeasy kit (Qiagen, Germany) and cDNA was generated using Superscript III RT system using manufacture's instructions (Life Technologies, Carlsbad, CA). Primers used in these assays are described in Supplementary file 3. Relative expression levels in in vitro time course differentiation experiments were normalized to total RNA. Relative levels of expression of spinal column tissues were normalized to Gapdh. PCR reactions were performed using SYBR Green PCR Master Mix according to the manufacturer's instructions in an ABI 7300 real time PCR machine (Applied Biosystems, Grand Island, NY).
Vector, plasmids and transfections
Taf9b and Taf9 cDNAs were obtained from Open Biosystems clones (TAF9B clone ID#30468965, TAF9 clone ID#5006430) and cloned into p3xFLAG-CMV-10 vector to obtain p3xFLAG-CMV-TAF9B and -TAF9. Plasmids were transfected into 293T cells by lipofectamine 2000 (Life Technologies). Cells were collected 48 hr after transfection.
Co-Immunoprecipitations
Transfected 293T cells were lysed and the protein concentration was measured by the Bradford method. EB-MN differentiated for 8 days were collected and nuclear extract was prepared as previously described (Pugh, 1995) . Spinal column tissues were dissected from newborn mice, immediately frozen in liquid nitrogen, and stored at −80°C. Tissue samples were ground into powder in liquid nitrogen and cell lysis buffer was added to extract proteins. After centrifugation, the protein concentration was measured by the Bradford method. Indicated antibodies were mixed with protein A sepharose (GE Healthcare life science, Pittsburgh, PA) or protein G Dynabeads (Life technologies) for 1 hr at 4°C. Protein extracts (1 mg) were mixed with the antibodies/beads complexes for overnight at 4°C on a rotating wheel. The beads were washed three times with washing buffer containing 300 mM KCl and 0.05% NP-40 and once with washing buffer containing 100 mM KCl. Samples were boiled in SDS loading buffer for 5 min and analyzed by Western blotting using indicated antibodies.
Western blots and immunostainings
Western blots were performed using whole cell extracts and SDS-PAGE. Immunostainings of EB-MN were performed after fixing samples in 4% paraformaldehyde for 30 min at room temperature. Antibodies were incubated in PBS, 0.1% Triton X-100 and washed three times with PBS, 0.1% Triton X-100 for 10 min each time.
Antibodies
Antibodies used are anti-TBP (cat#51841; Abcam, Cambridge, Massachusetts), anti-TAF4 (cat#612054; BD Biosciences, San Jose, CA), anti-TAF7 (cat#H00006879-M01; Abnova, Taiwan), anti-TAF9B (cat#A303-810A; #G2306 and Bethyl Laboratories, Montgomery, TX), anti-TAF10 (Santa Cruz cat#102125), anti-OCT4 (Santa Cruz cat#8628, Dallas, Texas), anti-TUBB3 (cat#MMS435P; Covance, Princeton, New Jersey), anti-ACTB (cat#A2228; Sigma-Aldrich), anti-RNA POL2 (8WG16; Clone), anti-PCAF (cat#13124; Santa Cruz), anti-ISL1/2 (Gift from the Jessell Lab, Columbia University), anti-NANOG (cat#A300-397A; Bethyl Laboratories), anti-Ki67 (cat#16667; Abcam), anti-FLAG (cat#F3165; Sigma-Aldrich) and Rabbit IgG control (cat#46540; Abcam). TAF9B antibodies #G2306 were produced by injecting a peptide corresponding to residues 226-245 of TAF9B into rabbit by OpenBiosystems (GE Healthcare). Antiserum was tested for specificity using extracts from 293T cells transfected with p3xFLAG-CMV-TAF9B and -TAF9.
Cell cycle and apoptosis assays
Cell cycle was measured using BrdU Flow kit following manufacturer's instructions (cat#552598; BD Biosciences). Apoptosis was measured using PE annexin V apoptosis detection kit following manufacturer's instructions (cat#559763; BD Biosciences).
RNA-seq
Total RNA was isolated from cells or tissue extracts using RNeasy Kit (Qiagen) and 1.5 μg of total RNA was used to prepared Poly-A RNA-seq libraries following Illumina protocols. Samples were sequenced using Illumina Sequencers at the QB3 Vincent J Coates Genomics Sequencing Laboratory, UC Berkeley. Sequenced reads were mapped against RefSeq genes using TopHat ) and differentially expressed genes were determined using Cuffdiff (Trapnell et al., 2010) . Genes expressed more than 1 FPKM and with >twofold difference and p-value < 0.05 as calculated by Cuffdiff were considered as differentially expressed for scatter plots representations and for GO term analysis using DAVID Bioinformatic resources (Huang et al., 2009) .
Chromatin IP and ChIP-seq
ChIP-seq was performed using 1 mg of chromatin for each IP reaction using antibodies against TAF9B (#G2306), RNA POL2 (8WG16), and IgG control with EB-MN differentiated for 8 days. EB-MN samples were fixed with 0.5% formaldehyde for 10 min at room temperature and ChIPs were performed as described previously (Liu et al., 2011; Zhou et al., 2013b) . ChIP-qPCR experiments were performed using EB-MN samples differentiated for 6-8 days. ChIP-seq libraries were prepared following Illumina protocols and sequenced at the QB3 Vincent J Coates Genomics Sequencing Laboratory, UC Berkeley. Reads were mapped to UCSC version mm9 using Bowtie (Langmead et al., 2009) . ChIP-seq peaks were determined using MACS (Zhang et al., 2008 ) and significant peaks were associated to genes using GREAT default parameters (McLean et al., 2010) .
Mouse Taf9b KO
All animal experiments were performed in strict accordance with the recommendations in the guide for the care and use of laboratory animals of the National Institutes of Health and following the animal use protocol (#R007) approved by the Animal Care and Use Committee (ACUC) of the University of California, Berkeley. Taf9b KO mouse was generated in the UC Berkeley transgenic facility by injecting Taf9b KO murine ES cells (TAF9b ) and chimeric mice were obtained. Taf9b heterozygous animals were backcrossed to WT C57BL/6 mice to obtain Taf9b heterozygous mice without the albino phenotype (Tyr
c-2J
). Mice were genotyped by PCR using primers detecting WT and KO sequences. Primers sequences are available in Supplementary file 3. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. 
Author contributions
Additional files
Major datasets
The following dataset was generated:
Author ( 
